John W. Henson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John W. Henson has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
D N Louis
2 shared publicationsDavid N. Louis
Massachusetts General Hospital
2 shared publicationsR Gilberto Gonzalez
2 shared publicationsAllan F. Thornton
From the Brain Tumor Center and Spine Tumor Center (Drs. Henson and Thornton)Department of Radiation Oncology (Dr. Thornton), Department of Pathology and Neurosurgical Service (Dr. Louis), Massachusetts General Hospital, Boston; and Harvard Medical School (Drs. Henson, Thornton, and Louis), Boston, MA
1 shared publication- Andreas von Deimling
Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany
1 shared publication April F. Eichler
Pappas Center for Neuro-Oncology, Boston, MA 02114, USA
1 shared publication
Latest Publications
- Open Access
- 13 February 2008
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 29 (3) , 419-424
Brain Tumor Imaging in Clinical Trials
SUMMARY: There are substantial challenges in the radiologic evaluation of tumor size during clinical trials, and it is important for neuroradiologists to have a firm understanding of these issues. This review will examine measurement approaches, response criteria, selection of lesions for measurement, technical imaging considerations, interval between tumor measurements and response confirmation, and validity of imaging as a measure of efficacy.
- 13 February 2008
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 29 (3) , 419-424
Open AccessBrain Tumor Imaging in Clinical Trials
SUMMARY: There are substantial challenges in the radiologic evaluation of tumor size during clinical trials, and it is important for neuroradiologists to have a firm understanding of these issues. This review will examine measurement approaches, response criteria, selection of lesions for measurement, technical imaging considerations, interval between tumor measurements and response confirmation, and validity of imaging as a measure of efficacy.
- 23 October 2007
- Published by Wolters Kluwer Health in Neurology
- Vol. 69 (17) , 1712-1714
International science at the annual meeting of the American Academy of Neurology
The annual meeting of the American Academy of Neurology (AAN) is a major venue for presentation of the latest disease-related clinical and basic neurologic research and is attended by a large number of neurologists from countries outside the United States and Canada. One-third of annual meeting attendees and abstract submissions are international in origin, with wide variations between countries and world regions, and this proportion has remained stable for the past 5 years. By comparison, international neurologists constitute 12% (n = 2,485) of AAN membership, and international membership has declined slightly over the past 5 years compared to a 15% increase from the United States and Canada. The scientific topics covered by international abstracts are similar to those from the United States and Canada. Abstract acceptance rates are 15% lower for international submissions than for those from the United States and Canada although variations between countries are seen. Three times more European neurologists attend the annual meeting than are AAN members whereas Asian neurologists are more likely to be AAN members than to attend the annual meeting. The AAN is working to understand and address the issues that affect international physicians’ decisions to participate in the annual meeting.
- 23 October 2007
- Published by Wolters Kluwer Health in Neurology
- Vol. 69 (17) , 1712-1714
International science at the annual meeting of the American Academy of Neurology
The annual meeting of the American Academy of Neurology (AAN) is a major venue for presentation of the latest disease-related clinical and basic neurologic research and is attended by a large number of neurologists from countries outside the United States and Canada. One-third of annual meeting attendees and abstract submissions are international in origin, with wide variations between countries and world regions, and this proportion has remained stable for the past 5 years. By comparison, international neurologists constitute 12% (n = 2,485) of AAN membership, and international membership has declined slightly over the past 5 years compared to a 15% increase from the United States and Canada. The scientific topics covered by international abstracts are similar to those from the United States and Canada. Abstract acceptance rates are 15% lower for international submissions than for those from the United States and Canada although variations between countries are seen. Three times more European neurologists attend the annual meeting than are AAN members whereas Asian neurologists are more likely to be AAN members than to attend the annual meeting. The AAN is working to understand and address the issues that affect international physicians’ decisions to participate in the annual meeting.
- Open Access
- 1 July 2007
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 9 (3) , 373-377
Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate
Methotrexate (MTX) is a widely used chemotherapeutic agent that can cause acute, subacute, and chronic neurological complications. Subacute MTX neuro
- 1 July 2007
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 9 (3) , 373-377
Open AccessDiffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate
Methotrexate (MTX) is a widely used chemotherapeutic agent that can cause acute, subacute, and chronic neurological complications. Subacute MTX neuro
- Open Access
- 1 July 2006
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 8 (3) , 280-283
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1
The emergence of temozolomide as an effective alkylating agent with little acute toxicity or cumulative myelosuppression has led to protracted course
- 1 July 2006
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 8 (3) , 280-283
Open AccessTreatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1
The emergence of temozolomide as an effective alkylating agent with little acute toxicity or cumulative myelosuppression has led to protracted course
- 1 March 2006
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (3) , 337-341
Treatment of Glioblastoma Multiforme
Review from JAMA Neurology — Treatment of Glioblastoma Multiforme — A New Standard
- 1 March 2006
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (3) , 337-341
Treatment of Glioblastoma Multiforme
Review from JAMA Neurology — Treatment of Glioblastoma Multiforme — A New Standard
- 1 September 2005
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 74 (2) , 151-154
Alterations in p53, p21, and MIB-1 Labeling Index in Primary Human Astrocytomas Following Radiation Therapy
- 1 September 2005
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 74 (2) , 151-154
Alterations in p53, p21, and MIB-1 Labeling Index in Primary Human Astrocytomas Following Radiation Therapy
- 1 March 2005
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (3) , 167-175
MRI in treatment of adult gliomas
- 1 March 2005
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (3) , 167-175
MRI in treatment of adult gliomas
- 1 July 2004
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 4 (4) , 665-671
Neuroimaging in glioma therapy
The introduction of computed tomographic and magnetic resonance imaging into clinical practice is among the most important of all advances in the care of patients with brain tumors. Diffuse astrocytomas of the adult cerebral hemispheres are unique among human tumors for the degree to which their imaging features correlate with pathologic characteristics and clinical behavior. However, there is still little understanding of the value of various imaging features in measuring response and progression in brain tumors. This review focuses on some of the unsolved problems in the use of neuroimaging in measuring the response of brain tumors to therapy.
- 1 July 2004
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 4 (4) , 665-671
Neuroimaging in glioma therapy
The introduction of computed tomographic and magnetic resonance imaging into clinical practice is among the most important of all advances in the care of patients with brain tumors. Diffuse astrocytomas of the adult cerebral hemispheres are unique among human tumors for the degree to which their imaging features correlate with pathologic characteristics and clinical behavior. However, there is still little understanding of the value of various imaging features in measuring response and progression in brain tumors. This review focuses on some of the unsolved problems in the use of neuroimaging in measuring the response of brain tumors to therapy.
- 1 December 2000
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 26 (6) , 544-552
Molecular genetics of radiographically defined de novo glioblastoma multiforme
Glioblastoma multiforme (GBM) represents the final endpoint of anaplastic progression in astrocytomas. GBM which arise without clinical evidence of a prior low‐grade astrocytoma (LGA) have been designated de novo GBM, and are thought to develop rapidly from initial tumour formation. However, a purely clinical definition of de novo GBM does not exclude a long‐standing, asymptomatic low‐grade tumour. This study therefore sought to determine the genetic features of a unique group of cases in which GBMs were documented to have arisen radiographically in defined period of time (radiographically defined de novo GBM). Clinical and genetic features were examined in a group of 11 patients with a histological diagnosis of high‐grade astrocytoma at first biopsy and radiographically defined de novo GBM. The mean age of the patients at tumour diagnosis was 62 years (range 32–87). Six of 11 tumours arose in the temporal lobes. Eight of 11 tumours had epidermal growth factor receptor (EGFR) overexpression, and EGFR gene amplification was found in five of the six analysed cases. Overexpression of p53 was observed in only one tumour, and a TP53 mutation was present in this case. p16 immunostaining was undetectable in 10 cases, and homozygous deletion of CDKN2A was observed in four of the six studied tumours. pRb expression was lost in four tumours. Mutations in the PTEN gene were detected in two of six cases. The results in this unique group of cases confirms the prior hypothesis that the profile of genetic alterations in de novo GBM is distinct from that of GBM arising from a known LGA, and that these specific genetic pathways promote the rapid development of GBM.
- 1 December 2000
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 26 (6) , 544-552
Molecular genetics of radiographically defined de novo glioblastoma multiforme
Glioblastoma multiforme (GBM) represents the final endpoint of anaplastic progression in astrocytomas. GBM which arise without clinical evidence of a prior low‐grade astrocytoma (LGA) have been designated de novo GBM, and are thought to develop rapidly from initial tumour formation. However, a purely clinical definition of de novo GBM does not exclude a long‐standing, asymptomatic low‐grade tumour. This study therefore sought to determine the genetic features of a unique group of cases in which GBMs were documented to have arisen radiographically in defined period of time (radiographically defined de novo GBM). Clinical and genetic features were examined in a group of 11 patients with a histological diagnosis of high‐grade astrocytoma at first biopsy and radiographically defined de novo GBM. The mean age of the patients at tumour diagnosis was 62 years (range 32–87). Six of 11 tumours arose in the temporal lobes. Eight of 11 tumours had epidermal growth factor receptor (EGFR) overexpression, and EGFR gene amplification was found in five of the six analysed cases. Overexpression of p53 was observed in only one tumour, and a TP53 mutation was present in this case. p16 immunostaining was undetectable in 10 cases, and homozygous deletion of CDKN2A was observed in four of the six studied tumours. pRb expression was lost in four tumours. Mutations in the PTEN gene were detected in two of six cases. The results in this unique group of cases confirms the prior hypothesis that the profile of genetic alterations in de novo GBM is distinct from that of GBM arising from a known LGA, and that these specific genetic pathways promote the rapid development of GBM.
- 25 January 2000
- Published by Wolters Kluwer Health in Neurology
- Vol. 54 (2) , 518
Spinal cord astrocytoma: Response to PCV chemotherapy
Article abstract Information regarding the value of chemotherapy for spinal cord astrocytomas that progress after irradiation is limited. We describe a patient whose conus medullaris astrocytoma responded to PCV (procarbazine, lomustine, and vincristine) chemotherapy after failing radiation and cisplatin-based chemotherapy. PCV should be considered in patients with progressive spinal cord astrocytomas.
- 25 January 2000
- Published by Wolters Kluwer Health in Neurology
- Vol. 54 (2) , 518
Spinal cord astrocytoma: Response to PCV chemotherapy
Article abstract Information regarding the value of chemotherapy for spinal cord astrocytomas that progress after irradiation is limited. We describe a patient whose conus medullaris astrocytoma responded to PCV (procarbazine, lomustine, and vincristine) chemotherapy after failing radiation and cisplatin-based chemotherapy. PCV should be considered in patients with progressive spinal cord astrocytomas.